Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Veel heterogeniteit in resistente NSCLC-tumoren
apr 2024 | Longoncologie
mrt 2024
nov 2023
sep 2023